Posttransplant Cyclophosphamide as GVHD Prophylaxis for Peripheral Blood Stem Cell HLA-Mismatched Unrelated Donor Transplant

Investigators enrolled 38 patients with hematologic malignancies scheduled to undergo MMUD-HCT onto 1 of 2 conditioning strata: myeloablative using fludarabine and fractionated total body irradiation or reduced intensity with fludarabine/melphalan.